EN
EN
2025-6-27
Zhongjia Biomedical leads the formulation of China’s first group standard for the preparation specifications of human blood-derived natural killer cell preparations, leading a new future of standardized cell therapy.
Introduction: In the golden era of cell therapy technology accelerating toward clinical application, China’s biopharmaceutical industry has achieved an important breakthrough! On April 2, Shenzhen Zhongjia Biomedical Technology Co., Ltd. (hereinafter “Zhongjia Biomedical”) officially received an honorary certificate from the China Food and Drug Quality and Safety Enterprise Promotion Association – as the leading drafting unit, the group standard Specifications for Preparation of Human Blood-Derived Natural Killer Cell Preparations (Standard No. T/FDSA 0064-2025), formulated under Zhongjia Biomedical’s leadership, was officially approved, marking that China’s NK cell preparation process has entered a new stage of standardization and normalization.
I. From “follower” to “leader”: why can Zhongjia Biomedical become a “standard setter”?
Cell therapy is the fourth major cancer treatment after surgery, radiotherapy and chemotherapy. Among them, natural killer cells (NK cells), with advantages such as natural anti-tumor activity, strong targeting, and few side effects, have become a research hotspot in the current immunotherapy field. However, due to the lack of unified preparation standards, the industry once faced problems such as uneven preparation processes and inconsistent quality control, severely restricting the clinical transformation efficiency of NK cell therapy.

As a national high-tech enterprise deeply engaged in the cell therapy field for many years, Zhongjia Biomedical stands out with three core advantages:
Deep technical accumulation: it holds independent intellectual property rights and was among the earliest to research NK cell isolation, expansion and cryopreservation technology, and has built a GMP-compliant intelligent cell preparation platform.
Rich clinical experience: it cooperates with more than 30 top-tier hospitals nationwide in clinical research on NK cell therapy for malignant solid tumors and hematologic malignancies, accumulating more than 10,000 preparation cases.
Forward-looking standardization awareness: as early as 2022 it took the lead in launching R&D of a “whole-process quality control system for NK cell preparations”, proactively uniting industry experts, research institutions and clinical institutions to jointly advance standard formulation.
“Leading the formulation of a group standard is not only recognition of Zhongjia Biomedical’s technical strength, but also a heavy social responsibility,” said Zhongjia Biomedical in an interview. “We hope to build a ‘safety net’ for the industry through standardization, so that more high-quality cell therapies can benefit patients.”
II. What is “new” about this standard? Three highlights!
The Specifications for Preparation of Human Blood-Derived Natural Killer Cell Preparations (T/FDSA 0064-2025), after 18 months of research, demonstration and revision, has formulated 12 core technical indicators and 8 key quality control points covering the whole chain of NK cell preparations from “donor screening – cell collection – isolation and expansion – quality testing – storage and transportation”, filling the gap in the standard for NK cell preparation in China:
1. Whole-process traceability system: establish a donor information database to achieve full-process traceability from cell source to clinical application, strictly guarding the bottom line of biosafety.
2. Dual control of activity and efficacy: add key functional testing indicators such as NK cell killing activity and cytokine secretion function to ensure the clinical efficacy of the preparations.
3. Smart production guidance: provide standardized operation procedures (SOP) for pain points such as automated preparation equipment compatibility and process parameter optimization, lowering the technical threshold for small and medium-sized enterprises.
Industry experts commented: “The implementation of this standard will promote NK cell therapy to leap from ‘laboratory research’ to ‘clinical popularization’, is expected to shorten the new drug application cycle by more than 30%, and accelerate innovative therapies benefiting patients.”
III. The “Zhongjia responsibility” behind standardization: making cell therapy warmer
Driven by the “Healthy China 2030” plan, China’s cell therapy market is expected to exceed 50 billion yuan by 2025. But behind the rapid development of the industry is patients’ urgent need for “safe, effective and accessible” therapies. Zhongjia Biomedical’s leading of this standard formulation is a vivid practice in response to the national “innovation-driven development” strategy:
For the industry: establish a technical benchmark, guide resource integration, avoid “redundant construction”, and promote high-quality industrial development.
For clinical practice: reduce preparation costs through standardization, so more tumor patients can afford and use innovative therapies.
For society: use the “standard” as a link to connect the whole chain of research, production, clinical and supervision, building an ecosystem of collaborative innovation across “industry, academia, research, medicine and inspection”.
As Zhongjia Biomedical said: “We have always believed that real technological innovation must not only ‘reach the sky’ – breaking through key technologies, but also ‘stand on the ground’ – turning research results into patients’ hope for survival. This standard is our commitment to the industry.”
Conclusion: From a “standard follower” to a “standard setter”, every step of Zhongjia Biomedical’s progress stems from reverence for and deep cultivation of the cell therapy cause. With the implementation of the T/FDSA 0064-2025 standard, we have every reason to expect a more standardized and more dynamic cell therapy industry ecosystem is taking shape, and Zhongjia Biomedical will continue to be driven by technological innovation, writing a “standard answer sheet” that belongs to Chinese biopharmaceuticals.
[Interactive topic] What do you think cell therapy standardization means to ordinary patients? Welcome to leave your views in the comments! Shenzhen Zhongjia Biomedical Technology Co., Ltd. – making cell therapy safer, more effective and more accessible. Official website: http://www.zjbiotech.com
Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?
2026-10-23
Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors
2026-9-28
Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research
2026-9-28
New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction
2026-9-28
Great News! Another Zhongjia Medium Gets FDA DMF Filing
2026-7-23